8-K
filed June 14, 2023, 7:59 PM ET
ticker LSTA
CIK 0000320017
other material
confidence high
sentiment neutral
materiality 0.15
Lisata shareholders re-elect two Class I directors, approve equity plan amendments
LISATA THERAPEUTICS, INC.
- Re-elected Cynthia L. Flowers and Erkki Ruoslahti as Class I directors to 2026 term; 3.76M and 3.77M votes for respectively.
- Approved amendment to 2018 Equity Incentive Plan adding 400,000 shares; 3.53M for.
- Approved amendment to 2017 ESPP increasing shares to 68,333; 3.76M for.
- Ratified Grant Thornton as independent auditor for FY2023; 5.68M for.
- Non-binding advisory approval of executive compensation; 3.71M for.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
LISATA THERAPEUTICS, INC. shareholders approved The stockholders approved an amendment to 2017 Employee Stock Purchase Plan that increases the number of shares available under the plan to 68,333. at the 2023-06-14 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-06-14
Exact text from the filing
Proposal 3. The stockholders approved an amendment to 2017 Employee Stock Purchase Plan that increases the number of shares available under the plan to 68,333. The final voting results with respect to this Proposal were as follows: 3,757,925 votes for; 380,753 votes against; 3,240 votes abstaining and 1,681,571 broker non-votes.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
LISATA THERAPEUTICS, INC. shareholders approved The stockholders re-elected Cynthia L. Flowers, M.B.A. and Erkki Ruoslahti, M.D., Ph.D. as Class I directors to serve until the annual meeting to be held in 2026. at the 2023-06-14 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-14
Exact text from the filing
Proposal 1 . The stockholders re-elected Cynthia L. Flowers, M.B.A. and Erkki Ruoslahti, M.D., Ph.D. as Class I directors to serve until the annual meeting to be held in 2026. The final voting results with respect to Cynthia L. Flowers, M.B.A. were as follows: 3,764,936 votes for; 347,436 votes against; 29,546 votes abstaining and 1,681,571 broker non-votes. The final voting results with respect to Erkki Ruoslahti, M.D., Ph.D., were as follows: 3,773,219 votes for; 358,127 votes against; 10,572 votes abstaining and 1,681,571 broker non-votes.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
LISATA THERAPEUTICS, INC. shareholders approved The stockholders approved an amendment to the Lisata Therapeutics, Inc. 2018 Equity Incentive Compensation Plan (the "Plan") to increase the number of shares of common stock that may be issued under the Plan by 400,000. at the 2023-06-14 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-06-14
Exact text from the filing
Proposal 2. The stockholders approved an amendment to the Lisata Therapeutics, Inc. 2018 Equity Incentive Compensation Plan (the "Plan") to increase the number of shares of common stock that may be issued under the Plan by 400,000. The final voting results with respect to this Proposal were as follows: 3,527,880 votes for; 611,722 votes against; 2,316 votes abstaining and 1,681,571 broker non-votes.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
LISATA THERAPEUTICS, INC. shareholders approved The stockholders approved, on a non-binding advisory basis, the executive compensation of the Company's named executive officers as disclosed in the Proxy Statement. at the 2023-06-14 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-06-14
Exact text from the filing
Proposal 5. The stockholders approved, on a non-binding advisory basis, the executive compensation of the Company's named executive officers as disclosed in the Proxy Statement. The final voting results with respect to this Proposal were as follows: 3,710,921 votes for; 401,195 votes against; 29,802 votes abstaining and 1,681,571 broker non-votes.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
LISATA THERAPEUTICS, INC. shareholders approved The stockholders ratified the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-06-14 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-14
Exact text from the filing
Proposal 4. The stockholders ratified the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The final voting results with respect to this Proposal were as follows: 5,680,246 votes for; 120,655 votes against; 22,588 votes abstaining and 0 broker non-votes.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.